Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response

1. A method to modulate an immune system response in a human or animal who has cancer, comprising administering to the human or animal an effective amount of one or more immunogenic compositions for modulating the immune system comprising

a therapeutically effective amount of three or more synthetic antigenic agents or natural antigenic agents, or fractions and combinations thereof, comprising pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) selected from at least two groups consisting of: (A) antigenic agents with molecular patterns associated with bacteria, (B) antigenic agents with molecular patterns associated with viruses, (C) antigenic agents with molecular patterns associated with fungi and yeasts, (D) antigenic agents with molecular patterns associated with protozoa, (E) antigenic agents with molecular patterns associated with helminthes, and (F) antigenic agents with molecular patterns associated with prions; and

one or more physiologically acceptable carriers, excipients, diluents or solvents.

2. The method according to claim 1 , wherein the cancer is carcinoma, adenocarcinoma, melanoma, sarcoma, malignant astrocytoma, hepatoma, hypernephroma, lymphoma or melanoma.

3. The method according to claim 1 , further comprising administering to the human or animal one or more cytokines and/or chemokines.

4. The method according to claim 3 , further comprising administering to the human or animal GM-CSF, IL2, IL4, IL5, IL7, IL12, IL15, IL21 and/or interferon gamma.

5. The method according to claim 4 , further comprising administering to the human or animal IL2.

6. The method according to claim 1 , wherein the method is used before, during or after antibiotic therapy, chemotherapy, radiation therapy, therapy with antibodies and antisera, use of hormones, use of cytokines, use of chemokines, use of neurohormones, use of peptides, use of antivirals, use of phytotherapy, vitamin supplementation, supplementation with other cofactors or prosthetic agents, transplantation of cells or tissues, methods of therapeutic or prophylactic vaccination, gene therapy, surgery, or homeopathic therapy.

7. The method according to claim 1 , wherein the immunogenic composition for modulating the immune system comprises from 4 to 20 antigenic agents selected from the group consisting of

antigenic agents derived from: dornase, yeast extract, oidiomycin, purified protein derivative of Koch's bacillus (PPD), prions, streptokinases, Streptococcus toxoid, diphtheria toxoid, tetanus toxoid, Koch's original tuberculin, Aspergillus spp., Candida spp., Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Cryptosporidium spp., Dermatophytes, Entamoeba hystolitica, Enterobius vermicularis, Enterococcus faecalis, Epidermophyton floccosum, Escherichia coli, Giardia lamblia, Haemophilus influenzae, Microsporum canis, Mycobacterium spp., Neisseria gonorrhoeae , Human papillomavirus , Polio virus, Proteus spp., Salmonella spp., Serratia spp., Shigella spp., Staphylococcus spp., Strongyloides stercoralis, Streptococcus spp., Toxoplasma gondii, Trichomonas vaginalis, trichophytin, Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes , yellow fever virus, hepatitis B virus, rubella virus, varicella zoster virus, variola virus, mumps virus, measles virus, herpes virus, or vaccinia virus,

synthetic analogues presenting pathogen-associated molecular patterns (PAMPS) associated with these antigenic agents, and

synthetic analogues presenting danger-associated molecular patterns (DAMPS) associated with these antigenic agents.

8. The method of claim 1 , wherein the immunogenic composition for modulating the immune system comprises lysate of inactivated Mycobacterium bovis , purified protein derivative of M. tuberculosis , lysate of inactivated Staphylococcus aureus , lysate of inactivated Staphylococcus epidermidis , lysate of inactivated Streptococcus pyogenes , lysate of inactivated Streptococcus pneumoniae , lysate of inactivated Enterococcus faecalis Streptokinase, dornase, lysate of inactivated Candida albicans , lysate of inactivated Candida glabrata , lysate of inactivated Epidermophyton floccosum , lysate of inactivated Microsporum canis , lysate of inactivated Trichophyton mentagrophytes of the interdigitale variety, lysate of inactivated enteropathogenic Escherichia coli , lysate of inactivated Salmonella bongori , lysate of inactivated Salmonella enterica and lysate of inactivated Salmonella subterranea.

9. The method according to claim 1 , wherein the immunogenic composition for modulating the immune system comprises from 0.001 to 1 ng/ml of lysate of inactivated Mycobacterium bovis, 0.001 to 1 ng/ml of purified protein derivative of M tuberculosis, 0.1 to 100 μg/ml of lysate of inactivated Staphylococcus aureus, 0.1 to 100 μg/ml of lysate of inactivated Staphylococcus epidermidis; 0.1 to 100 μg/ml of lysate of inactivated Streptococcus pyogenes; 0.1 to 100 μg/ml of lysate of inactivated Streptococcus pneumoniae; 0.1 to 100 μg/ml of lysate of inactivated Enterococcus faecalis, 0.01 to 10 μg/ml of streptokinase, 0.01 to 10 μg/ml of dornase; 0.1 to 100 μg/ml of lysate of inactivated Candida albicans; 0.1 to 100 μg/ml of lysate of inactivated Candida glabrata, 0.1 to 100 μg/ml of lysate of inactivated Epidermophyton floccosum; 0.1 to 100 μg/ml of lysate of inactivated Microsporum canis, 0.1 to 100 μg/ml of lysate of inactivated Trichophyton mentagrophytes of the interdigitale variety; 0.1 to 100 μg/ml of lysate of inactivated enteropathogenic Escherichia coli; 0.1 to 100 μg/ml lysate of inactivated Salmonella bongori, 0.1 to 100 μg/ml lysate of inactivated Salmonella enterica and 0.1 to 100 μg/ml of lysate of inactivated Salmonella subterranea.

10. The method according to claim 1 , wherein the immunogenic composition comprises at least three natural or synthetic antigen agents from different microorganisms.

11. The method according to claim 1 , wherein the immunogenic composition comprises at least four natural or synthetic antigen agents from different microorganisms.

12. The method according to claim 1 , wherein administering comprises administering systemically and/or locally on the human or animal, and the method further comprises:

ensuring the contact of the one or more immunogenic compositions with dendritic cells or other antigen presenting cells (APCs) of the human or animal;

optionally administering prosthetic agents to strengthen the metabolism and therefore the immune system of the human or animal, and

optionally administering other medications or specific treatments.

13. The method according to claim 7 , wherein the

Aspergillus spp. is selected from the group consisting of Aspergillus flavus, Aspergillus fumigatus , and Aspergillus terreus;

Candida spp. is selected from the group consisting of Candida albicans, Candida glabrata , and Candida parapsilosis;

Mycobacterium spp. is selected from the group consisting of Mycobacterium bovis, Mycobacterium leprae , and Mycobacterium tuberculosis;

Proteus spp. is selected from the group consisting of Proteus mirabilis, Proteus penerii , and Proteus vulgaris;

Salmonella spp. is selected from the group consisting of Salmonella bongori and Salmonella enterica;

Serratia spp. is selected from the group consisting of Serratia liquefaciens and Serratia marcescens;

Shigella spp. is selected from the group consisting of Shigella flexneri and Shigella sonnei;

Staphylococcus spp. is selected from the group consisting of Staphylococcus aureus , and Staphylococcus epidermidis ; and

Streptococcus spp. is selected from the group consisting of Streptococcus bovis, Streptococcus viridans, Streptococcus equinus, Streptococcus pneumoniae , and Streptococcus pyogenes.